Show simple item record

ITHACA, a randomized multicenter phase 3 study of Isatuximab in combination with Lenalidomide and Dexamethasone in high-risk smoldering Multiple Myeloma: safety run-in preliminary results

dc.contributor.authorKoh, Youngil
dc.contributor.authorGhobrial, Irene
dc.contributor.authorMartinez-Lopez, Joaquin
dc.contributor.authorRodriguez-Otero, Paula
dc.contributor.authorLepine, Lucie
dc.contributor.authorMace, Sandrine
dc.contributor.authorOprea, Corina
dc.contributor.authorMateos, Maria-Victoria
dc.contributor.authorDevisme, Christine
dc.contributor.authorDubin, Franck
dc.contributor.authorSchjesvold, Fredrik
dc.contributor.authorPeceliunas, Valdas
dc.contributor.authorLeleu, Xavier
dc.contributor.authorKim, Jin Seok
dc.contributor.authorBesisik, Sevgi Kalayoglu
dc.contributor.authorHungria, Vania
dc.contributor.authorHermansen, Emil
dc.contributor.authorde la Rubia, Javier
dc.contributor.authorQuach, Hang
dc.contributor.authorPrince, Miles
dc.contributor.authorParmar, Gurdeep
dc.date.accessioned2021-12-10T12:27:47Z
dc.date.available2021-12-10T12:27:47Z
dc.identifier.citationGhobrial I., Rodriguez-Otero P., Koh Y., Martinez-Lopez J., Parmar G., Prince M., Quach H., de la Rubia J., Hermansen E., Hungria V., et al., "ITHACA, a randomized multicenter phase 3 study of Isatuximab in combination with Lenalidomide and Dexamethasone in high-risk smoldering Multiple Myeloma: safety run-in preliminary results", CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, cilt.21, 2021
dc.identifier.issn2152-2650
dc.identifier.othervv_1032021
dc.identifier.otherav_be09d9a7-e1ea-476f-8197-884cf8344e0e
dc.identifier.urihttp://hdl.handle.net/20.500.12627/173933
dc.language.isoeng
dc.subjectOnkoloji
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectHEMATOLOJİ
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.subjectHealth Sciences
dc.subjectHematology
dc.subjectOncology
dc.subjectHematoloji
dc.subjectİç Hastalıkları
dc.subjectDahili Tıp Bilimleri
dc.titleITHACA, a randomized multicenter phase 3 study of Isatuximab in combination with Lenalidomide and Dexamethasone in high-risk smoldering Multiple Myeloma: safety run-in preliminary results
dc.typeMakale
dc.relation.journalCLINICAL LYMPHOMA MYELOMA & LEUKEMIA
dc.contributor.departmentHarvard University , ,
dc.identifier.volume21
dc.contributor.firstauthorID2770412


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record